The College FixOpinion

UMich cardiologist says school right to pause trans procedures for kids

A University of Michigan cardiologist and medical school professor said his employer is right to pause pediatric transgender ...

FDA Clears HeartLung’s AI-CVD®, Enabling the Broadest Opportunistic Cardiovascular & Multisystem CT Screening Platform

FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and ...

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant ...
Health on MSN

Strength Training vs. Cardio: Which Is Better for Heart Health, Muscle Growth, and Longevity?

A combination of cardio and strength training is crucial for heart health, muscle strength, and healthy aging.

Genethon Signs Licensing Agreement With AskBio for the Development of an Investigational Gene Therapy for Pompe Disease

Genethon, a leading laboratory in gene therapy for rare diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with AskBio, a gene therapy company wholly owned ...

Southampton woman who died in bed named as inquest opens

An inquest has opened into the death of a Southampton woman who died in bed. Yvette Karen Brunsdon, 64, of Heathfield Close, died at her home on September 27, a court heard. The inquest into her death ...

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...

Transneural Therapeutics Presents Preclinical Data on Lead Candidate TN-001 at 64th Annual Meeting of ACNP (2026)

Poster presentation highlighted promising pharmacology and behavioral results on lead candidate, TN-001, in preclinical studies. TN-001 is under development for both major depressive disorder (MDD) ...
EurekAlert!

Inflammation and mitochondrial dysfunction in cirrhotic cardiomyopathy: therapeutic implications

Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms ...
Kent Live on MSN

Staff training conducted at Kent prison healthcare unit where prisoner died eight hours after arriving

It was "probable" a nurse inserted an airway incorrectly, meaning Josh Tarrant didn't get oxygen for more than 16 minutes, an ...

Solid Biosciences Inc.: Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...

Solid Biosciences Inc.: Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia

SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected ...